NEW YORK, NY / ACCESSWIRE / September 8, 2022 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a leading provider of therapeutics for men's health, today announces newly published third party data in the International Journal of UrologyEfficacy and safety of avanafil as compared with sildenafil in the treatment of erectile dysfunction by Kumar, Pathade, Gupta, Goyal, Rath, Thakre, Sanmukhani, and Mittal, detailing the Company's PDE 5 inhibitor STENDRA® (avanafil) tablets in a non-inferiority, head-to-head study compared to sildenafil (Viagra) which was conducted in India. The primary efficacy endpoint was improvement in erectile function based on domain score of the International Index of Erectile Function (IIEF). Some secondary endpoints included, the percentage of patients reaching a normal IIEF-EF score; percentage of successful vaginal penetrations and successful intercourse in the two groups; and percentage of doses with some erection in 15 mins in the two groups. The Zydus Healthcare-sponsored study, also showed rapid onset of action of STENDRA as demonstrated by a questionnaire determining whether some erection occurred within 15 minutes of dosing (see important safety information below).
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today provides positive...
NEW YORK, Feb. 4, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Petros or the Company) (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that it has formed a steering committee to develop expanded patient access initiatives, including non-prescription or Over the Counter (OTC) status strategies, for its STENDR
Battered after a spectacular failure with its Alzheimer’s drug candidate, Neurotrope Biosciences is being absorbed by a privately-held company that makes an erectile dysfunction (ED) treatment.